Mersana Therapeutics (MRSN) Financials

Mersana Therapeutics Inc (MRSN) is a biopharmaceutical company that focuses on the development and commercialization of antibody-drug conjugates (ADCs) for the treatment of cancer. The company's ADC platform utilizes its proprietary Fleximer technology to create novel ADCs with improved stability, potency, and tolerability. Mersana's lead product candidate, XMT-1522, is being evaluated in clinical trials for the treatment of various types of solid tumors. The company has also partnered with other pharmaceutical companies, including Takeda and Merck, to develop and commercialize additional ADC candidates.

According to Mersana's income statement, the company reported total revenue of $10.5 million for the latest fiscal year. Gross profit was $6.8 million, resulting in a gross margin of 64.8%. The company's operating expenses, including research and development and general and administrative expenses, totaled $51.2 million. As a result, Mersana reported a net loss of $44.4 million for the year. Despite the net loss, the company's cash equivalents and marketable securities totaled $172.6 million as of the end of the fiscal year, providing a strong financial position to support its ongoing research and development efforts.

On the balance sheet, Mersana Therapeutics Inc (MRSN) reported total assets of $238.9 million. This includes cash and cash equivalents, marketable securities, and other assets such as property and equipment. The company has a relatively low level of total debt, with only $3.9 million reported. Total liabilities, which include accounts payable and accrued expenses, totaled $26.3 million. The difference between total assets and total liabilities reflects the stockholders' equity, which was reported at $212.6 million.

In terms of cash flow, Mersana reported a net cash used in operating activities of $43.1 million for the latest fiscal year. This primarily reflects the company's ongoing investments in research and development and general corporate activities. Net cash used in investing activities was $11.5 million, mainly due to purchases of property and equipment. Net cash provided by financing activities was $216.1 million, primarily from proceeds from the issuance of common stock in a public offering.

In summary, Mersana Therapeutics Inc (MRSN) is a biopharmaceutical company focused on the development of novel ADCs for the treatment of cancer. While the company has reported a net loss in recent years, it maintains a strong financial position with a substantial amount of cash and cash equivalents. With ongoing clinical development and partnerships with pharmaceutical companies, Mersana is well-positioned to continue advancing its pipeline of ADC candidates.